Eric Lefkofsky’s Impressive Resume

A well known business man and entrepreneur, Eric Lefkofsky has been making a name for himself for quite some time. Co-founder and CEO of Tempus, a leading technology company, Lefkofsky has started and built a number of successful businesses over the years. His determination and passion for excellence are signs that he and his work will be around for some time to come.

Lefkofsky is a Michigan native. Born to a mom who was a school teacher and a father who worked as an engineer, Lefkofsky learned about value of hard work from a young age. After watching his parents for years, he eventually chose to attend the University of Michigan where he earned his degree in 1991. Just two years later he continued on at University of Michigan Law School where Eric Lefkofsky earned his Juris Doctor. His education would be the spring board for what would come next in his life.

Lefkofsky would begin working in the business world. Along with his close friend Brad Keywell, Lefkofsky created Brandon Apparel, an apparel company based out of Wisconsin. Next, Lefkofsky and Keywell started an Internet company called Starbelly that specialized in promotional products. Then in 2001, the duo co-founded InnerWorkings, a n organization that provided print procurement services for mid-sized companies. Four years later he would start a freight logistics company called Echo Global Logistics.

Lefkofsky started many companies bun not were quite as impressive as This website later became known by the more popular Groupon achieved massive success, so much so it received a more than six billion dollar buyout offer from Google. The company however would not be sold and would go on to have continued success. Just the next year Groupon raised $950 million in private funding to learn more: click here.

Eric Lefkofsky is also a faithful giver. He and his wife, formed a charitable trust called the Lefkofsky Foundation. This group gives to causes that support both educational and scientific causes. Eric Lefkofsky has proven to be a great business man. He is sure to be around for many more years to come.

The Cancer Treatment Centers of America (CTCA) Spice Up Its Services by Implementing the Clinical Pathway Program

CTCA has joined hands with Allscripts Sunrise and NantHealth to roll out the Clinical Pathways program. The program will link up NantHealth’s eviti® solutions and Allscript’s electronic health record (HER), thus enhancing an efficient cancer treatment process and smooth delivery of clinical services by medical practitioners. NantHealth brought with it a clinical operating system, NantOS that incorporates a database for cancer care.

Benefits to Patients

As stated in this article, Clinical Pathways will integrate a compilation of cancer research reports from oncologists drawn from across the United States and beyond. These reports improve cancer treatment, which makes them the best patient-centered medical advancement in the recent times. This integration will also link up patients and medical practitioners as well as individual partner patients with the clinical teams that they may require. With this kind of partnership, patients will have a clear understanding of their diagnosis and treatment process. On top of that, Clinical Pathways will provide patient treatment data to health insurance providers to hasten insurance approval when the need arises. Patients at any of the five CTCA hospitals will have access to these services.

Benefits to Physicians

According to Wikipedia, physicians will also have their fair share of benefits from Clinical Pathways. The program will offer them a platform to solicit reliable and accurate medical information from Evidence-Based Medical Library. The library has more than 2,700 cancer treatment prescriptions and regimens compiled from government agencies and oncology associations. These regimens details expected treatment costs and clinical outcomes.

About CTCA

CTCA is a conglomeration of five hospitals that specializes in cancer treatment across the U.S. Founded by Richard Stephenson in 1988, the organization was initially headquartered in Illinois but was later moved to Boca Raton, Florida.

During the first 17 years, the organization was operating in only one hospital: the Midwestern Regional Medical Center in Illinois. The other four hospitals have been established in four different states, including Pennsylvania, Oklahoma, Arizona, and Georgia.

For more information on CTCA follow them on Facebook and Twitter.

The Continued Success of Seattle Genetics.

In a recent article by the Business Journal, it discussed the growth of the biotechnology company Seattle Genetics. The recent success surrounding is mentioned in the Puget Sound Business Journal; particularly Seattle Genetics’s plan to market 12 more drugs as well as hire 100 more employees. The success of Seattle Genetics, however, is not without present CEO, Clay Siegall. Before discussing his contribution to Seattle Genetics, it is valuable to understand what the article says about Seattle Genetics and how it has found success.

The article begins by discussing how Seattle Genetics is developing various drugs to combat specific types of cancer. Their commercialized drug, Adcetris, is currently being tested in more than 70 trials, which the article states. Adcetris is a drug that is intended to treat Hodgkin Lymphoma. The article also mentions how Seattle Genetics is also developing a drug to treat breast cancer and bladder cancer. Their ambition to continue their success by growing as a business has led to the hiring of 800 new employees, which the article states. Seattle Genetics overall is showing its determination to develop beneficial drugs and its success with the number of individuals they are hiring.

Seattle’s Genetics success, however, is not without CEO, Clay Siegall. As co-founder of Seattle Genetics since 1998, he has helped it earn over 330 million through public and private financing, according to one article. Siegall’s experience lends him credibility as a board of director in different institutions.  In an interview, Clay Siegall shares some of his thoughts as to how he continues to build on the success of Seattle Genetics. His response to some of the questions were about how he intends to develop cancer-treating drugs, such as ADCETRIS. Siegall explains how he and Seattle Genetics is also developing a 7 clinical-stage programs to combat leukemia, lymphoma, and other types of cancer. Siegall ultimately shows how he is a major contributor to the success of Seattle Genetics.